Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.83 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL28932383 | 1.00 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ANFKB1 | |
| Cadaverine Tartrate SCHEMBL28636687 | 0.92 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ANFKB1 | |
| Cadaverine Tartrate SCHEMBL15660786 | 0.92 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ANFKB1 | |
| Cadaverine Tartrate SCHEMBL2276011 | 0.92 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ANFKB1 | |
| Cadaverine Tartrate SCHEMBL1431070 | 0.91 | TSHR (1.00) | TSHRTP53CYP2C9PDE4ANFKB1 | |
| Tartaric Acid SCHEMBL5762 | 0.91 | TSHR (1.00) | TSHRTP53CYP2C9PDE4ANFKB1 | |
| Cadaverine Tartrate SCHEMBL1062721 | 0.91 | TSHR (1.00) | TSHRTP53CYP2C9PDE4ANFKB1 | |
| Cadaverine Tartrate SCHEMBL22768 | 0.91 | TSHR (1.00) | TSHRTP53CYP2C9PDE4ANFKB1 | |
| Cadaverine Tartrate SCHEMBL848 | 0.91 | TSHR (1.00) | TSHRTP53CYP2C9PDE4ANFKB1 | |
| Cadaverine Tartrate SCHEMBL116846 | 0.91 | TSHR (1.00) | TSHRTP53CYP2C9PDE4ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104098478-A | Aminoalcohol resolution method | ANHUI BIOCHEM UNITED PHARMACEUTICAL CO LTD | 2014-10-15 | — | — | CN | claimed |
| CN-115998677-A | Meta-hydroxylamine bitartrate injection and preparation method thereof | 北京世桥生物制药有限公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-218231844-U | Tartaric acid bitartrate hydroxylamine injection configuration partial shipment device | 北京市永康药业有限公司 | 2023-01-06 | — | — | CN | disclosed |
| CN-112245387-B | Composition and preparation method of m-hydroxylamine bitartrate injection | 南京泽恒医药技术开发有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-112326810-A | Pretreatment of m-hydroxylamine bitartrate injection and separation and determination of enantiomer | 南京斯泰尔医药科技有限公司 | 2021-02-05 | — | — | CN | disclosed |
| CN-112245387-A | Composition and preparation method of m-hydroxylamine bitartrate injection | 南京泽恒医药技术开发有限公司 | 2021-01-22 | — | — | CN | disclosed |
| CN-104098478-B | Aminoalcohol resolution method | 安徽贝克联合制药有限公司 | 2017-05-17 | — | — | CN | disclosed |
| CN-104072381-B | Preparation method for optically pure aminoalcohol hydrochloride | 安徽贝克联合制药有限公司 | 2017-04-12 | — | — | CN | disclosed |
| CN-104098478-A | Aminoalcohol resolution method | ANHUI BIOCHEM UNITED PHARMACEUTICAL CO LTD | 2014-10-15 | — | — | CN | disclosed |
| CN-104098478-A | Aminoalcohol resolution method | ANHUI BIOCHEM UNITED PHARMACEUTICAL CO LTD | 2014-10-15 | — | — | CN | disclosed |
| US-5534525-A | Lactam derivatives | ZENECA LIMITED (GB) | 1996-07-09 | — | — | US | disclosed |
| EP-0714392-A1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1996-06-05 | — | — | EP | disclosed |
| EP-0667858-A1 | 4-CARBOXOAMIDO PIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1995-08-23 | — | — | EP | disclosed |
| WO-1995015961-A1 | BICYCLIC HETEROCYCLES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1995-06-15 | — | — | WO | disclosed |
| WO-1995012577-A1 | NOVEL 4-PIPERIDINYL SUBSTITUTED LACTAMES AS NEUROKININ 2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA | ZENECA LIMITED (GB) | 1995-05-11 | — | — | WO | disclosed |
| WO-1995005377-A1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1995-02-23 | — | — | WO | disclosed |
| CN-1098094-A | The heterocycle that aryl replaces | ZENECA LTD (GB) | 1995-02-01 | — | — | CN | disclosed |
| EP-0630887-A1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LIMITED (GB) | 1994-12-28 | — | — | EP | disclosed |
| CN-1094723-A | Carboxamide derivative | ZENECA LTD (GB) | 1994-11-09 | — | — | CN | disclosed |
| WO-1994010146-A1 | 4-CARBOXOAMIDO PIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1994-05-11 | — | — | WO | disclosed |